China News Service, February 19. According to Kyodo News, Japan’s new crown vaccine was the first to be vaccinated in Nagano, Hyogo, Okayama, and Hiroshima counties on the 18th.
Statistics from Kyodo News show that at least 16 hospitals in 8 prefectures have started vaccination.
On the same day, Prime Minister Yoshihide Suga inspected the hospital in Tokyo where the vaccination had begun, and said that "I feel that the medical staff are looking forward to the effect. It will be provided to the people across the country as soon as possible."
On January 7, local time, in Tokyo, Japan, people took to the streets wearing masks.
According to reports, in Japan, 40,000 people were first vaccinated.
The Ministry of Health, Labour and Welfare collects half of the data to investigate safety.
Statistics from Kyodo News show that at least 16 hospitals in 8 prefectures have started vaccination.
On the 19th, it is planned to further expand the implementation area, and it is expected that the vaccination will begin in all 100 hospitals across the country targeted for next week.
Japanese Prime Minister Yoshihide Suga inspected the hospital in Tokyo that began vaccination on the 18th and said that "I feel that the medical staff are looking forward to the effect. It will be provided to the people of the whole country as soon as possible."
There are also medical institutions in order to eliminate anxiety about vaccination and strive to be foolproof.
Murayama Medical Center (Tokyo) held a briefing session for employees on the 18th.
This is to deepen the understanding of adverse reactions and let everyone consider whether to vaccinate.
To avoid affecting general diagnosis and treatment, the center plans to vaccinate on the 20th.
On the other hand, Japan's KM Biologics (Kumamoto City), which is committed to the research and development of the new crown vaccine, submitted a clinical trial plan to the central government on the 17th, striving to start clinical trials for adults in late March.
Japan began to inoculate vaccines produced by the US pharmaceutical giant Pfizer on the 17th.
Although it lags behind overseas in research and development, Sonoda pointed out, “If you rely on imports, national funds (for purchases) will flow overseas, and it is impossible to predict whether the supply will be stable. It should also be considered that it will be popular every year in the future and require repeated vaccination. Situation", stressing the need for cheap domestic vaccines.
The company developed an inactivated vaccine made from a virus that has eliminated its toxicity, which is different from Pfizer's vaccine production method.
Inactivated vaccines have been effective in infectious diseases such as polio. Sonoda said that "the risk of adverse reactions can be expected to become lower."
The company started research and development in May 2020, and the effectiveness was confirmed in animal experiments.
From late March 2021, small-scale clinical trials will begin with human subjects.
It is planned to go on sale after conducting tens of thousands of trials from autumn to winter.